Ivermectin for COVID-19: real-time meta analysis of 63 studies
… the probability that an ineffective treatment generated results as positive as the 63 studies is estimated to be 1 in 1 trillion
… Those denying the efficacy of treatments share responsibility
… The evidence base is much larger … than typically used to approve drugs
… Merck has a ~$1.2B agreement to supply molnupiravir to the US government, if it receives EUA or approval
… Ivermectin is off-patent
… Japan requested Merck conduct clinical trials early in the pandemic and they declined
